Economy · News reference
B. Riley sees 40+ biotech catalysts ahead as rising rates pressure XBI, setting up a key test for the sector during the Q3 2026 earnings season.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Eton Pharmaceuticals released preliminary results from a pilot study of ET-700, an investigational extended-release zinc acetate formulation for Wilson disease, showing improved tolerability compared to GALZIN.
Eton Pharmaceuticals exceeded expectations in Q3 2026 with revenues of $57.9M (158% YoY growth) and raised full-year revenue guidance to over $175M with adjusted EBITDA margins above 40%. The company achieved its $200M annualized revenue run-rate target five quarters ahead of schedule, driven primarily by HEMANGEOL sales. Eton is preparing for an April 2027 LIBERVANT launch and advancing its pipeline including ASN-001 and ET-900.
Harmony Biosciences reported Q3 EPS of 81 cents, missing consensus estimates of $1.00, despite 12% revenue growth to $269 million. Higher R&D spending, a $25 million MSN milestone charge, and royalty expenses pressured profitability. The company reaffirmed its 2026 Wakix revenue guidance of $1-$1.04 billion, supported by sustained patient demand and 400 net patient additions. The pipeline includes promising Phase I results for BP-205 and ongoing late-stage studies for pitolisant formulations and epilepsy programs.
RBC Capital Markets issued commentary suggesting that Cytokinetics' product, Myqorzo, could begin to positively impact the company's revenue starting in 2027.
Leerink Partners has maintained its 'Outperform' rating on Cytokinetics while adjusting its price target downward from $103 to $100.
Eton Pharmaceuticals reported record third-quarter 2026 revenue of $57.9 million, a 158% year-over-year increase, and raised its full-year 2026 financial guidance.